{"success":true,"data":{"pressRelease":{"id":"152562","rtpr_id":"nGNXbZrKXK-20260924","ticker":"NANOB","exchange":"Euronext Paris","all_tickers":["NANOB"],"title":"NANOBIOTIX Provides First Half 2026 Operational and Financial Update","author":"Globe Newswire","published_at":"2026-09-24T20:15:00.292Z","article_body":"* Promising early results reported from full cohort analysis of the completed\ndose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900\n(NBTXR3) for patients with inoperable, locoregionally recurrent non-small cell\nlung cancer (“NSCLC”) amenable to re-irradiation\n* Strengthened financial position through an oversubscribed ~€86 million\nglobal follow-on offering completed in May 2026, extending cash runway into\n2029\n* Acceptable safety profile and promising initial efficacy responses observed\nin Johnson & Johnson-led Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3)\nin Stage 3 unresectable NSCLC\n* U.S. FDA clearance for protocol amendment to the Johnson & Johnson-led Phase\n3 NANORAY-312 study evaluating JNJ-1900 (NBTXR3) in locally advanced platinum\nineligible head and neck cancer\n* €110.9 million in cash and cash equivalents as of June 30, 2026\nPARIS and CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX\n(https://www.globenewswire.com/Tracker?data=3KMx2xAUz9ydJ4kcTLEm4ZcgRZauJVESdEPLbjRyT3fL7D1A0AFFIvV5hPP6YolgR-9HwD08tcz8FpO9QGiZXQ==)\n(Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage\nbiotechnology company pioneering nanotherapeutic approaches to expand\ntreatment possibilities for patients with cancer and other major diseases,\ntoday provided an update on operational progress and reported financial\nresults for the first six months of 2026.\n\n“Our progress in the first half of 2026 continues to support our belief that\na physics-based approach to the design and development of nanotherapeutics has\nthe potential to revolutionize treatment possibilities for millions of\npatients around the world,” said Laurent Levy, Chief Executive Officer and\nChairman of the Executive Board at Nanobiotix. “The JNJ-1900 (NBTXR3)\nclinical development program continued to produce encouraging data across\nmultiple indications, and adjustments to the Phase 3 NANORAY-312 protocol\nstreamlined the study toward the final analysis. Longstanding shareholders and\nnew investors alike expressed confidence in our vision through our recent\ncapital raise. We enter the second half strategically, operationally, and\nfinancially equipped to continue supporting Nanoradioenhancer JNJ-1900\n(NBTXR3) and advancing next wave nanotherapeutic platforms such as\nNanoprimer.”\n\nOperational Highlights\n* New data from Phase 1 NSCLC study sponsored by The University of Texas MD\nAnderson Cancer Center (“UT MD Anderson”) presented at 2026 WCLC Meeting:\n* At a median follow-up of 12 months, the one-year locoregional control rate\nwas 79%. One-year local progression-free survival (“LPFS”) was 61%, and\none-year overall survival (“OS”) was 70% in evaluable patients.\n* Investigators concluded that JNJ-1900 (NBTXR3) may permit clinically\nmeaningful local control using a substantially lower re-irradiation dose.\n* All 24 patients completed treatment with JNJ-1900 (NBTXR3) plus\nre-irradiation with no dose-limiting toxicities\n* No Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3) or to the\ninjection procedure were reported\n* The recommended Phase 2 dose was established at 33% of gross tumor volume\n \n* Included in the Euronext Tech Leaders segment and Euronext Tech Leaders\nIndex, a Euronext flagship initiative dedicated to increasing the visibility\nand attractiveness of Europe’s leading and high-growth technology companies\namong international investors.\n* Closed a global follow-on offering with underwriters’ over-allotment\noption fully exercised, bringing total gross proceeds to approximately €86\nmillion that will support continued develop of Nanobiotix’s broader\ntherapeutic platforms\n* Part 1 data from Johnson & Johnson (“J&J”)-led Phase 2 JNJ-1900 (NBTXR3)\nStudy in Unresectable Stage 3 NSCLC (CONVERGE) presented at ELCC 2026 and\nupdated at ESTRO 2026 * Initial investigator-reported efficacy responses\nobserved in 7 patients following the full treatment regimen of JNJ-1900\n(NBTXR3) given prior to concurrent chemoradiotherapy, and consolidation with\ndurvalumab) showed: * Overall response rate (“ORR”) = 85.7% (6/7 patients)\nreported at ESTRO 2026 * In the same cohort of 7 patients, ORR observed at\nearlier time point and reported at ELCC 2026 was 71.4% (5/7 patients)\n \n* Complete response rate (“CRR”) = 57.1% (4/7 patients) reported at ESTRO\n2026 * With the current standard of care, concurrent chemoradiation therapy\n(cCRT) + durvalumab, depth of response remains limited in Stage 3 unresectable\nNSCLC with very low rates of complete response (~15%)(1)\n \n* Deepening response over time suggests potential for long-term durability\n* The procedure demonstrated an acceptable safety profile without serious\ntreatment-emergent adverse events (TEAEs)\n \n* Early results suggest that intratumoral/intranodal injection of JNJ-1900\n(NBTXR3) is feasible and can be performed safely in patients with stage III\nunresectable NSCLC\n \n* Protocol amendment to J&J-led global Phase 3 JNJ-1900 (NBTXR3) study in\nCisplatin-ineligible Head and Neck Cancer (NANORAY-312) * Eliminated\npreviously planned interim analysis eliminated and modified the final analysis\nto include fewer events than originally planned to be conducted sooner\n \n* New preclinical data presented at 2026 AACR Meeting * Pre-treatment with\nNanoprimer followed by administration of LNP-delivered recombinant DNA\n(“LNP-DNA”) designed for anti-tumor immunotherapy showed increased\nsystemic bioavailability, reduced hepatic toxicity, and reduced cGAS-STING\nrelated inflammation compared to LNP-DNA administered without the Nanoprimer\nHalf Year 2026 Financial Results\n\nRevenue and Other Income: Revenue and other income amounted to €5.6 million\nfor the six months ended June 30, 2026, as compared to €26.6 million for the\nsame period in 2025. This variance is mainly due to a significant one-off\nnon-cash revenue positive impact amounting to €21.2 million recorded over\nthe first half of 2025 in accordance with IFRS15 revenue recognition\naccounting principles, further to the transfer of NANORAY-312 study\nsponsorship to Johnson & Johnson. In addition, Revenue and Other Income for\nthe six months ended June 30, 2026 also included €3.1 million of clinical\nproduct supply sales to Johnson & Johnson (as compared to €3.4 million for\nthe same period in 2025) and research tax credit income amounting to €1.9\nmillion (as compared to €1.6 million for the same period in 2025).\n\nResearch and Development (“R&D”) Expenses: R&D expenses consist primarily\nof preclinical, clinical and manufacturing expenses including employee-related\npayroll costs and shared-based payment charges related to the development of\nJNJ-1900 (NBTXR3) and of new platforms. These R&D expenses for the six months\nending June 30 2026, were €12.7 million as compared to €14.5 million for\nthe same period in 2025. The €1.8 million favorable variance was primarily\ndriven by lower clinical development and JNJ-1900 (NBTXR3) production\nactivities in NANORAY-312 study further to the transfer of sponsorship to\nJohnson & Johnson, and by less patient recruitment on the studies Study 1100\nand lower UT MD Anderson studies expense during first half of 2026 as compared\nto the same period in 2025.\n\nSelling, General and Administrative (“SG&A”) Expenses: SG&A expenses\nconsist primarily of administrative employee-related payroll costs,\nshare-based payment charges, insurance, IP, legal, audit and other\nprofessional fees. Total SG&A expenses for the six months ending June 30,\n2026, were €10.8 million, as compared to €11.3 million for the same period\nin 2025. The €0.5 million favorable variance is mainly due to the impact of\nsocial charges related to stock-option plan and severance expenses occurred\nover the first half of 2025.\n\nNet loss: Net loss attributable to common shareholders for the six months\nending June 30, 2026, was €34.3 million, or a €0.70 basic loss per share.\nThis compares to a net loss attributable to common shareholders of €5.4\nmillion, or €0.11 basic loss per share, for the same period in 2025.\n\nCash and Cash Equivalents: Cash and Cash Equivalents as of June 30, 2026 were\n€110.9 million, compared to €52.8 million as of December 31, 2025.\n\nFinancial Guidance: Based on the current operating plan and financial\nprojections, the Company anticipates that the cash and cash equivalents of\n€110.9 million as of June 30, 2026 will fund its operations into 2029.\n\nAvailability of the Half Year 2026 Financial Reports\n\nThe 2026 half-year financial report has been filed with the French financial\nmarket authority (Autorité des marchés financiers) and with the U.S.\nSecurities and Exchange Commission on September 24, 2026. It is available to\nthe public on the Company’s website, www.nanobiotix.com.\n\nAbout JNJ-1900 (NBTXR3)\n\nJNJ-1900 (NBTXR3) is a novel, potentially first-in-class oncology product\ncomposed of functionalized hafnium oxide nanoparticles administered via\none-time intratumoral injection and activated by radiotherapy. The product\ncandidate’s mechanism of action (MoA) is designed to induce significant\ntumor cell death in the injected tumor when in the presence of radiotherapy,\nsubsequently triggering adaptive immune response and long-term anti-cancer\nmemory. Proof-of-concept was demonstrated in a randomized Phase 2/3 soft\ntissue sarcoma study sponsored by Nanobiotix in 2018.\n\nJNJ-1900 (NBTXR3) is being evaluated across multiple solid tumor indications\nas a single agent or combination therapy. Given the Company’s focus areas,\nand balanced against the scalable potential of NBTXR3, Nanobiotix has engaged\nin a collaboration strategy to expand development of the product candidate in\nparallel with its priority development pathways. Pursuant to this strategy, in\n2019 Nanobiotix entered into a broad, comprehensive clinical research\ncollaboration with The University of Texas MD Anderson Cancer Center to\nsponsor several Phase 1 and Phase 2 studies evaluating JNJ-1900 (NBTXR3)\nacross tumor types and therapeutic combinations.\n\nIn February 2020, the United States Food and Drug Administration granted\nregulatory Fast Track designation for the investigation of NBTXR3 activated by\nradiation therapy, with or without cetuximab, for the treatment of patients\nwith locally advanced HNSCC who are not eligible for platinum-based\nchemotherapy.\n\nIn 2023, Nanobiotix announced a license agreement for the global development\nand commercialization of JNJ-1900 (NBTXR3) with Janssen Pharmaceutica NV, a\nJohnson & Johnson company. Studies being led by Johnson & Johnson include\nNANORAY-312 (NCT04892173), a global, randomized Phase 3 study in\nplatinum-based chemotherapy-ineligible, locally advanced head and neck\nsquamous cell cancers; LUMIRAY (NCT07219212), a global, phase 1b, open-label\nstudy in locally advanced head and neck squamous cell cancers; and CONVERGE\n(NCT06667908), a phase 2, randomized, open-label, active-controlled study in\nlocally advanced and unresectable Stage III non-small cell lung cancer\n(NSCLC).\n\nAbout NANOBIOTIX\n\nNanobiotix is a late-stage clinical biotechnology company pioneering\ndisruptive, physics-based therapeutic approaches to revolutionize treatment\noutcomes for millions of patients; supported by people committed to making a\ndifference for humanity. The Company’s philosophy is rooted in the concept\nof pushing past the boundaries of what is known to expand possibilities for\nhuman life.\n\nIncorporated in 2003, Nanobiotix is headquartered in Paris, France and is\nlisted on Euronext Paris since 2012 and on the Nasdaq Global Select Market in\nNew York City since December 2020. The Company has subsidiaries in Cambridge,\nMassachusetts (United States) amongst other locations.\n\nNanobiotix is the owner of more than 30 umbrella patents associated with three\n(3) nanotechnology platforms with applications in 1) oncology; 2)\nbioavailability and biodistribution; and 3) disorders of the central nervous\nsystem.\n\nFor more information about Nanobiotix, visit us at www.nanobiotix.com or\nfollow us on LinkedIn and Twitter.\n\nDisclaimer\n\nThis press release contains “forward-looking” statements within the\nmeaning of the “safe harbor” provisions of the Private Securities\nLitigation Reform Act of 1995, including, but not limited to, statements\nregarding the use of proceed therefrom, and the period of time through which\nthe Company’s anticipates its financial resources will be adequate to\nsupport operations. Words such as “expects”, “intends”, “can”,\n“could”, “may”, “might”, “plan”, “potential”, “should”\nand “will” or the negative of these and similar expressions are intended\nto identify forward-looking statements. These forward-looking statements which\nare based on the Company’ management’s current expectations and\nassumptions and on information currently available to management. These\nforward-looking statements involve known and unknown risks, uncertainties and\nother factors that could cause actual results to differ materially from those\nimplied by the forward-looking statements, including risks related to\nNanobiotix’s business and financial performance, which include the risk that\nassumptions underlying the Company’s cash runway projections are not\nrealized. Further information on the risk factors that may affect company\nbusiness and financial performance is included in Nanobiotix’s Annual Report\non Form 20-F filed with the SEC on March 31, 2026 under “Item 3.D. Risk\nFactors”, in Nanobiotix’s 2025 universal registration document filed with\nthe AMF on March 31, 2026 under “chapter 1.5 Risk Factors”, and subsequent\nfilings Nanobiotix makes with the SEC and AMF from time to time, including the\nHalf-Year Report at June 30, 2026, which are available on the SEC’s website\nat www.sec.gov and on the AMF's website at www.amf.org, The forward-looking\nstatements included in this press release speak only as of the date of this\npress release, and except as required by law, Nanobiotix assumes no obligation\nto update these forward-looking statements publicly.\n\n Nanobiotix                                                                                                                                                                                                                                                                                                              \n Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com  Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 joanne.choi@nanobiotix.com  Ricky Bhajun Director, Investor Relations (EU) +33 (0) 79 97 29 99 investors@nanobiotix.com    \n Media Relations                                                                                                                                                                                                                                                                                                         \n France – HARDY Caroline Hardy +33 6 70 33 49 50 carolinehardy@outlook.fr                             Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com                                                                                                                      \n\n(1)Antonia SJ, et al. N Engl J Med. 2017.\n\nAttachment\n*     2026-09-24 -- NBTX -- 1H26 Financial Results -- FINAL\n(https://ml.globenewswire.com/Resource/Download/c952197f-7698-4e57-b03f-de0bfb86e9ac)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/36fb7b98-27d7-46cb-b989-fa31626657b8)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXbZrKXK-20260924","title":"NANOBIOTIX Provides First Half 2026 Operational and Financial Update","author":"Globe Newswire","ticker":"NANOB","created":"2026-09-24T20:15:00.292Z","tickers":["NANOB"],"exchange":"Euronext Paris","article_body":"* Promising early results reported from full cohort analysis of the completed\ndose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900\n(NBTXR3) for patients with inoperable, locoregionally recurrent non-small cell\nlung cancer (“NSCLC”) amenable to re-irradiation\n* Strengthened financial position through an oversubscribed ~€86 million\nglobal follow-on offering completed in May 2026, extending cash runway into\n2029\n* Acceptable safety profile and promising initial efficacy responses observed\nin Johnson & Johnson-led Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3)\nin Stage 3 unresectable NSCLC\n* U.S. FDA clearance for protocol amendment to the Johnson & Johnson-led Phase\n3 NANORAY-312 study evaluating JNJ-1900 (NBTXR3) in locally advanced platinum\nineligible head and neck cancer\n* €110.9 million in cash and cash equivalents as of June 30, 2026\nPARIS and CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX\n(https://www.globenewswire.com/Tracker?data=3KMx2xAUz9ydJ4kcTLEm4ZcgRZauJVESdEPLbjRyT3fL7D1A0AFFIvV5hPP6YolgR-9HwD08tcz8FpO9QGiZXQ==)\n(Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage\nbiotechnology company pioneering nanotherapeutic approaches to expand\ntreatment possibilities for patients with cancer and other major diseases,\ntoday provided an update on operational progress and reported financial\nresults for the first six months of 2026.\n\n“Our progress in the first half of 2026 continues to support our belief that\na physics-based approach to the design and development of nanotherapeutics has\nthe potential to revolutionize treatment possibilities for millions of\npatients around the world,” said Laurent Levy, Chief Executive Officer and\nChairman of the Executive Board at Nanobiotix. “The JNJ-1900 (NBTXR3)\nclinical development program continued to produce encouraging data across\nmultiple indications, and adjustments to the Phase 3 NANORAY-312 protocol\nstreamlined the study toward the final analysis. Longstanding shareholders and\nnew investors alike expressed confidence in our vision through our recent\ncapital raise. We enter the second half strategically, operationally, and\nfinancially equipped to continue supporting Nanoradioenhancer JNJ-1900\n(NBTXR3) and advancing next wave nanotherapeutic platforms such as\nNanoprimer.”\n\nOperational Highlights\n* New data from Phase 1 NSCLC study sponsored by The University of Texas MD\nAnderson Cancer Center (“UT MD Anderson”) presented at 2026 WCLC Meeting:\n* At a median follow-up of 12 months, the one-year locoregional control rate\nwas 79%. One-year local progression-free survival (“LPFS”) was 61%, and\none-year overall survival (“OS”) was 70% in evaluable patients.\n* Investigators concluded that JNJ-1900 (NBTXR3) may permit clinically\nmeaningful local control using a substantially lower re-irradiation dose.\n* All 24 patients completed treatment with JNJ-1900 (NBTXR3) plus\nre-irradiation with no dose-limiting toxicities\n* No Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3) or to the\ninjection procedure were reported\n* The recommended Phase 2 dose was established at 33% of gross tumor volume\n \n* Included in the Euronext Tech Leaders segment and Euronext Tech Leaders\nIndex, a Euronext flagship initiative dedicated to increasing the visibility\nand attractiveness of Europe’s leading and high-growth technology companies\namong international investors.\n* Closed a global follow-on offering with underwriters’ over-allotment\noption fully exercised, bringing total gross proceeds to approximately €86\nmillion that will support continued develop of Nanobiotix’s broader\ntherapeutic platforms\n* Part 1 data from Johnson & Johnson (“J&J”)-led Phase 2 JNJ-1900 (NBTXR3)\nStudy in Unresectable Stage 3 NSCLC (CONVERGE) presented at ELCC 2026 and\nupdated at ESTRO 2026 * Initial investigator-reported efficacy responses\nobserved in 7 patients following the full treatment regimen of JNJ-1900\n(NBTXR3) given prior to concurrent chemoradiotherapy, and consolidation with\ndurvalumab) showed: * Overall response rate (“ORR”) = 85.7% (6/7 patients)\nreported at ESTRO 2026 * In the same cohort of 7 patients, ORR observed at\nearlier time point and reported at ELCC 2026 was 71.4% (5/7 patients)\n \n* Complete response rate (“CRR”) = 57.1% (4/7 patients) reported at ESTRO\n2026 * With the current standard of care, concurrent chemoradiation therapy\n(cCRT) + durvalumab, depth of response remains limited in Stage 3 unresectable\nNSCLC with very low rates of complete response (~15%)(1)\n \n* Deepening response over time suggests potential for long-term durability\n* The procedure demonstrated an acceptable safety profile without serious\ntreatment-emergent adverse events (TEAEs)\n \n* Early results suggest that intratumoral/intranodal injection of JNJ-1900\n(NBTXR3) is feasible and can be performed safely in patients with stage III\nunresectable NSCLC\n \n* Protocol amendment to J&J-led global Phase 3 JNJ-1900 (NBTXR3) study in\nCisplatin-ineligible Head and Neck Cancer (NANORAY-312) * Eliminated\npreviously planned interim analysis eliminated and modified the final analysis\nto include fewer events than originally planned to be conducted sooner\n \n* New preclinical data presented at 2026 AACR Meeting * Pre-treatment with\nNanoprimer followed by administration of LNP-delivered recombinant DNA\n(“LNP-DNA”) designed for anti-tumor immunotherapy showed increased\nsystemic bioavailability, reduced hepatic toxicity, and reduced cGAS-STING\nrelated inflammation compared to LNP-DNA administered without the Nanoprimer\nHalf Year 2026 Financial Results\n\nRevenue and Other Income: Revenue and other income amounted to €5.6 million\nfor the six months ended June 30, 2026, as compared to €26.6 million for the\nsame period in 2025. This variance is mainly due to a significant one-off\nnon-cash revenue positive impact amounting to €21.2 million recorded over\nthe first half of 2025 in accordance with IFRS15 revenue recognition\naccounting principles, further to the transfer of NANORAY-312 study\nsponsorship to Johnson & Johnson. In addition, Revenue and Other Income for\nthe six months ended June 30, 2026 also included €3.1 million of clinical\nproduct supply sales to Johnson & Johnson (as compared to €3.4 million for\nthe same period in 2025) and research tax credit income amounting to €1.9\nmillion (as compared to €1.6 million for the same period in 2025).\n\nResearch and Development (“R&D”) Expenses: R&D expenses consist primarily\nof preclinical, clinical and manufacturing expenses including employee-related\npayroll costs and shared-based payment charges related to the development of\nJNJ-1900 (NBTXR3) and of new platforms. These R&D expenses for the six months\nending June 30 2026, were €12.7 million as compared to €14.5 million for\nthe same period in 2025. The €1.8 million favorable variance was primarily\ndriven by lower clinical development and JNJ-1900 (NBTXR3) production\nactivities in NANORAY-312 study further to the transfer of sponsorship to\nJohnson & Johnson, and by less patient recruitment on the studies Study 1100\nand lower UT MD Anderson studies expense during first half of 2026 as compared\nto the same period in 2025.\n\nSelling, General and Administrative (“SG&A”) Expenses: SG&A expenses\nconsist primarily of administrative employee-related payroll costs,\nshare-based payment charges, insurance, IP, legal, audit and other\nprofessional fees. Total SG&A expenses for the six months ending June 30,\n2026, were €10.8 million, as compared to €11.3 million for the same period\nin 2025. The €0.5 million favorable variance is mainly due to the impact of\nsocial charges related to stock-option plan and severance expenses occurred\nover the first half of 2025.\n\nNet loss: Net loss attributable to common shareholders for the six months\nending June 30, 2026, was €34.3 million, or a €0.70 basic loss per share.\nThis compares to a net loss attributable to common shareholders of €5.4\nmillion, or €0.11 basic loss per share, for the same period in 2025.\n\nCash and Cash Equivalents: Cash and Cash Equivalents as of June 30, 2026 were\n€110.9 million, compared to €52.8 million as of December 31, 2025.\n\nFinancial Guidance: Based on the current operating plan and financial\nprojections, the Company anticipates that the cash and cash equivalents of\n€110.9 million as of June 30, 2026 will fund its operations into 2029.\n\nAvailability of the Half Year 2026 Financial Reports\n\nThe 2026 half-year financial report has been filed with the French financial\nmarket authority (Autorité des marchés financiers) and with the U.S.\nSecurities and Exchange Commission on September 24, 2026. It is available to\nthe public on the Company’s website, www.nanobiotix.com.\n\nAbout JNJ-1900 (NBTXR3)\n\nJNJ-1900 (NBTXR3) is a novel, potentially first-in-class oncology product\ncomposed of functionalized hafnium oxide nanoparticles administered via\none-time intratumoral injection and activated by radiotherapy. The product\ncandidate’s mechanism of action (MoA) is designed to induce significant\ntumor cell death in the injected tumor when in the presence of radiotherapy,\nsubsequently triggering adaptive immune response and long-term anti-cancer\nmemory. Proof-of-concept was demonstrated in a randomized Phase 2/3 soft\ntissue sarcoma study sponsored by Nanobiotix in 2018.\n\nJNJ-1900 (NBTXR3) is being evaluated across multiple solid tumor indications\nas a single agent or combination therapy. Given the Company’s focus areas,\nand balanced against the scalable potential of NBTXR3, Nanobiotix has engaged\nin a collaboration strategy to expand development of the product candidate in\nparallel with its priority development pathways. Pursuant to this strategy, in\n2019 Nanobiotix entered into a broad, comprehensive clinical research\ncollaboration with The University of Texas MD Anderson Cancer Center to\nsponsor several Phase 1 and Phase 2 studies evaluating JNJ-1900 (NBTXR3)\nacross tumor types and therapeutic combinations.\n\nIn February 2020, the United States Food and Drug Administration granted\nregulatory Fast Track designation for the investigation of NBTXR3 activated by\nradiation therapy, with or without cetuximab, for the treatment of patients\nwith locally advanced HNSCC who are not eligible for platinum-based\nchemotherapy.\n\nIn 2023, Nanobiotix announced a license agreement for the global development\nand commercialization of JNJ-1900 (NBTXR3) with Janssen Pharmaceutica NV, a\nJohnson & Johnson company. Studies being led by Johnson & Johnson include\nNANORAY-312 (NCT04892173), a global, randomized Phase 3 study in\nplatinum-based chemotherapy-ineligible, locally advanced head and neck\nsquamous cell cancers; LUMIRAY (NCT07219212), a global, phase 1b, open-label\nstudy in locally advanced head and neck squamous cell cancers; and CONVERGE\n(NCT06667908), a phase 2, randomized, open-label, active-controlled study in\nlocally advanced and unresectable Stage III non-small cell lung cancer\n(NSCLC).\n\nAbout NANOBIOTIX\n\nNanobiotix is a late-stage clinical biotechnology company pioneering\ndisruptive, physics-based therapeutic approaches to revolutionize treatment\noutcomes for millions of patients; supported by people committed to making a\ndifference for humanity. The Company’s philosophy is rooted in the concept\nof pushing past the boundaries of what is known to expand possibilities for\nhuman life.\n\nIncorporated in 2003, Nanobiotix is headquartered in Paris, France and is\nlisted on Euronext Paris since 2012 and on the Nasdaq Global Select Market in\nNew York City since December 2020. The Company has subsidiaries in Cambridge,\nMassachusetts (United States) amongst other locations.\n\nNanobiotix is the owner of more than 30 umbrella patents associated with three\n(3) nanotechnology platforms with applications in 1) oncology; 2)\nbioavailability and biodistribution; and 3) disorders of the central nervous\nsystem.\n\nFor more information about Nanobiotix, visit us at www.nanobiotix.com or\nfollow us on LinkedIn and Twitter.\n\nDisclaimer\n\nThis press release contains “forward-looking” statements within the\nmeaning of the “safe harbor” provisions of the Private Securities\nLitigation Reform Act of 1995, including, but not limited to, statements\nregarding the use of proceed therefrom, and the period of time through which\nthe Company’s anticipates its financial resources will be adequate to\nsupport operations. Words such as “expects”, “intends”, “can”,\n“could”, “may”, “might”, “plan”, “potential”, “should”\nand “will” or the negative of these and similar expressions are intended\nto identify forward-looking statements. These forward-looking statements which\nare based on the Company’ management’s current expectations and\nassumptions and on information currently available to management. These\nforward-looking statements involve known and unknown risks, uncertainties and\nother factors that could cause actual results to differ materially from those\nimplied by the forward-looking statements, including risks related to\nNanobiotix’s business and financial performance, which include the risk that\nassumptions underlying the Company’s cash runway projections are not\nrealized. Further information on the risk factors that may affect company\nbusiness and financial performance is included in Nanobiotix’s Annual Report\non Form 20-F filed with the SEC on March 31, 2026 under “Item 3.D. Risk\nFactors”, in Nanobiotix’s 2025 universal registration document filed with\nthe AMF on March 31, 2026 under “chapter 1.5 Risk Factors”, and subsequent\nfilings Nanobiotix makes with the SEC and AMF from time to time, including the\nHalf-Year Report at June 30, 2026, which are available on the SEC’s website\nat www.sec.gov and on the AMF's website at www.amf.org, The forward-looking\nstatements included in this press release speak only as of the date of this\npress release, and except as required by law, Nanobiotix assumes no obligation\nto update these forward-looking statements publicly.\n\n Nanobiotix                                                                                                                                                                                                                                                                                                              \n Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com  Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 joanne.choi@nanobiotix.com  Ricky Bhajun Director, Investor Relations (EU) +33 (0) 79 97 29 99 investors@nanobiotix.com    \n Media Relations                                                                                                                                                                                                                                                                                                         \n France – HARDY Caroline Hardy +33 6 70 33 49 50 carolinehardy@outlook.fr                             Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com                                                                                                                      \n\n(1)Antonia SJ, et al. N Engl J Med. 2017.\n\nAttachment\n*     2026-09-24 -- NBTX -- 1H26 Financial Results -- FINAL\n(https://ml.globenewswire.com/Resource/Download/c952197f-7698-4e57-b03f-de0bfb86e9ac)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/36fb7b98-27d7-46cb-b989-fa31626657b8)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-24T20:15:00.331122461Z","server_sent_at_ms":1790280900331},"received_at":"2026-09-24T20:15:00.415Z","source_url":null},"analysis":{"id":"141366","press_release_id":"152562","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["net loss widened to €34.3 million from €5.4 million YoY, driven by lapping a €21.2 million one-off IFRS15 revenue benefit","revenue declined to €5.6 million from €26.6 million YoY","clinical efficacy results from small cohorts (7 and 24 patients) — early data, not registrational"],"eventType":"operations_update","narrative":"Nanobiotix reported promising full-cohort Phase 1 data for JNJ-1900 (NBTXR3) in inoperable recurrent NSCLC, with a 79% one-year locoregional control rate, 61% LPFS and 70% overall survival, and no dose-limiting toxicities among 24 patients.\n\nThe J&J-led Phase 2 CONVERGE study in unresectable Stage 3 NSCLC showed an 85.7% ORR (6/7) and 57.1% complete response rate — well above the ~15% complete-response benchmark for the current standard of care — and the FDA cleared a protocol amendment to the Phase 3 NANORAY-312 study that streamlines it toward the final analysis sooner.\n\nFinancially, the company closed an oversubscribed ~€86 million follow-on offering in May 2026, lifting cash to €110.9 million and extending the runway into 2029, despite a wider H1 net loss of €34.3 million (€0.70 basic loss per share) versus €5.4 million a year ago due to a €21.2 million one-off revenue benefit in H1 2025.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Strong early NSCLC efficacy plus a Phase 3 protocol streamlined toward earlier final analysis, backed by runway into 2029."},"keyFigures":{"revenue":"€5.6 million","guidance":"Cash of €110.9 million as of June 30, 2026 expected to fund operations into 2029","customDimensions":{"net_loss":"€34.3 million","rd_expenses":"€12.7 million","converge_crr":"57.1%","converge_orr":"85.7%","sga_expenses":"€10.8 million","cash_prior_year_end":"€52.8 million","phase1_nsclc_1yr_os":"70%","cash_and_equivalents":"€110.9 million","phase1_nsclc_1yr_lpfs":"61%","offering_gross_proceeds":"~€86 million","phase1_nsclc_1yr_locoregional_control":"79%"}},"quotedText":"At a median follow-up of 12 months, the one-year locoregional control rate was 79%. One-year local progression-free survival (“LPFS”) was 61%, and one-year overall survival (“OS”) was 70% in evaluable patients.","namedEntities":{"people":[{"name":"Laurent Levy","role":"CEO and Chairman of the Executive Board"},{"name":"Brandon Owens","role":"VP, Communications"},{"name":"Joanne Choi","role":"VP, Investor Relations (US)"},{"name":"Ricky Bhajun","role":"Director, Investor Relations (EU)"}],"products":["JNJ-1900 (NBTXR3)","Nanoprimer","LNP-DNA"],"companies":[{"name":"Nanobiotix","ticker":"NBTX","relationship":"filer"},{"name":"Johnson & Johnson","relationship":"partner (licensee of JNJ-1900/NBTXR3)"},{"name":"The University of Texas MD Anderson Cancer Center","relationship":"clinical research collaborator"},{"name":"Janssen Pharmaceutica NV","relationship":"J&J licensee entity"}],"dollarAmounts":[{"amount":"~€86 million","context":"gross proceeds of May 2026 global follow-on offering"},{"amount":"€110.9 million","context":"cash and cash equivalents as of June 30, 2026"},{"amount":"€5.6 million","context":"revenue and other income for six months ended June 30, 2026"},{"amount":"€34.3 million","context":"net loss attributable to common shareholders, H1 2026"},{"amount":"€12.7 million","context":"R&D expenses H1 2026"},{"amount":"€10.8 million","context":"SG&A expenses H1 2026"},{"amount":"€3.1 million","context":"clinical product supply sales to Johnson & Johnson H1 2026"}]},"materialImpact":{"score":3,"reasoning":"A broad H1 operational update with encouraging Phase 1 NSCLC data (79% one-year locoregional control), a CONVERGE Phase 2 ORR of 85.7%, FDA clearance of a streamlined Phase 3 protocol amendment, and cash runway extended into 2029 via an ~€86M oversubscribed offering. Positive but not a single binary catalyst."},"tickerRelevance":{"others":[],"primary":"NANOB"},"globalImportance":35,"audienceRelevance":30,"eventTypeSecondary":["clinical_trial","earnings"],"importanceComponents":{"eventDepth":"multiple positive readouts but none registrational","tickerTier":"mid/small-cap biotech (dual-listed Nasdaq/Euronext)","eventGravity":"routine half-year update with positive pipeline data","sectorWeight":"biotech clinical catalysts carry outsized stock sensitivity"}},"event_type":"operations_update","event_type_secondary":["clinical_trial","earnings"],"sentiment":"bullish","material_impact_score":3,"narrative":"Nanobiotix reported promising full-cohort Phase 1 data for JNJ-1900 (NBTXR3) in inoperable recurrent NSCLC, with a 79% one-year locoregional control rate, 61% LPFS and 70% overall survival, and no dose-limiting toxicities among 24 patients.\n\nThe J&J-led Phase 2 CONVERGE study in unresectable Stage 3 NSCLC showed an 85.7% ORR (6/7) and 57.1% complete response rate — well above the ~15% complete-response benchmark for the current standard of care — and the FDA cleared a protocol amendment to the Phase 3 NANORAY-312 study that streamlines it toward the final analysis sooner.\n\nFinancially, the company closed an oversubscribed ~€86 million follow-on offering in May 2026, lifting cash to €110.9 million and extending the runway into 2029, despite a wider H1 net loss of €34.3 million (€0.70 basic loss per share) versus €5.4 million a year ago due to a €21.2 million one-off revenue benefit in H1 2025.","key_figures":{"revenue":"€5.6 million","guidance":"Cash of €110.9 million as of June 30, 2026 expected to fund operations into 2029","customDimensions":{"net_loss":"€34.3 million","rd_expenses":"€12.7 million","converge_crr":"57.1%","converge_orr":"85.7%","sga_expenses":"€10.8 million","cash_prior_year_end":"€52.8 million","phase1_nsclc_1yr_os":"70%","cash_and_equivalents":"€110.9 million","phase1_nsclc_1yr_lpfs":"61%","offering_gross_proceeds":"~€86 million","phase1_nsclc_1yr_locoregional_control":"79%"}},"named_entities":{"people":[{"name":"Laurent Levy","role":"CEO and Chairman of the Executive Board"},{"name":"Brandon Owens","role":"VP, Communications"},{"name":"Joanne Choi","role":"VP, Investor Relations (US)"},{"name":"Ricky Bhajun","role":"Director, Investor Relations (EU)"}],"products":["JNJ-1900 (NBTXR3)","Nanoprimer","LNP-DNA"],"companies":[{"name":"Nanobiotix","ticker":"NBTX","relationship":"filer"},{"name":"Johnson & Johnson","relationship":"partner (licensee of JNJ-1900/NBTXR3)"},{"name":"The University of Texas MD Anderson Cancer Center","relationship":"clinical research collaborator"},{"name":"Janssen Pharmaceutica NV","relationship":"J&J licensee entity"}],"dollarAmounts":[{"amount":"~€86 million","context":"gross proceeds of May 2026 global follow-on offering"},{"amount":"€110.9 million","context":"cash and cash equivalents as of June 30, 2026"},{"amount":"€5.6 million","context":"revenue and other income for six months ended June 30, 2026"},{"amount":"€34.3 million","context":"net loss attributable to common shareholders, H1 2026"},{"amount":"€12.7 million","context":"R&D expenses H1 2026"},{"amount":"€10.8 million","context":"SG&A expenses H1 2026"},{"amount":"€3.1 million","context":"clinical product supply sales to Johnson & Johnson H1 2026"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-24T20:15:09.689Z","global_importance":35,"audience_relevance":30,"importance_components":{"eventDepth":"multiple positive readouts but none registrational","tickerTier":"mid/small-cap biotech (dual-listed Nasdaq/Euronext)","eventGravity":"routine half-year update with positive pipeline data","sectorWeight":"biotech clinical catalysts carry outsized stock sensitivity"}},"durationMs":9254,"modelName":"glm-5.3-flashx"}}